Raxibacumab (Human Genome Sciences, Inc.)


Welcome to the PulseAid listing for the Raxibacumab drug offered from Human Genome Sciences, Inc.. This Anthrax Protective Antigen-directed Antibody [EPC],Anthrax Protective Antigen-directed Antibody Interactions [MoA] pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: Human Genome Sciences, Inc.
NON-PROPRIETARY NAME: raxibacumab
SUBSTANCE NAME: RAXIBACUMAB
TYPE: HUMAN PRESCRIPTION DRUG
PHARMA CLASS: Anthrax Protective Antigen-directed Antibody [EPC],Anthrax Protective Antigen-directed Antibody Interactions [MoA]
ROUTE: INTRAVENOUS
DOSAGE FORM: INJECTION
MARKETING CATEGORY NAME: BLA
START MARKETING DATE: 2012-12-14
END MARKETING DATE: 0000-00-00


Raxibacumab HUMAN PRESCRIPTION DRUG Details:

Item DescriptionRaxibacumab from Human Genome Sciences, Inc.
LABELER NAME: Human Genome Sciences, Inc.
DEA SCHEDULE:
ACTIVE STRENGTH: 50(mg/mL)
START MARKETING DATE: 2012-12-14
END MARKETING DATE: 0000-00-00
PRODUCT ID: 49401-103_ac00d3a1-b7ad-4ec7-a870-fbc25d883176
PRODUCT NDC: 49401-103
APPLICATION NUMBER: BLA125349

Other RAXIBACUMAB Pharmaceutical Manufacturers / Labelers:

Manufacturer / LabelerProprietary Name
Human Genome Sciences, Inc.Raxibacumab